Cancer Research, Statistics, and Treatment (Jan 2021)

Bevacizumab in recurrent glioma: Variable doses, volatile benefits

  • Sujith Kumar Mullapally,
  • Pankaj Kumar Panda

DOI
https://doi.org/10.4103/crst.crst_172_21
Journal volume & issue
Vol. 4, no. 3
pp. 576 – 577

Abstract

Read online

No abstracts available.